The lived experience of Hepatitis C and its treatment among injecting drug users: Qualitative synthesis

Qualitative Health Research

Volumn 19, Issue 9, 2009, Pages 1321-1334

  Treloar, Carla ^a   Rhodes, Tim ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Health care; Hepatitis C; Lived experience; Meta ethnography; Substance use

Indexed keywords

ANTIVIRAL THERAPY; ARTICLE; ATTITUDE TO ILLNESS; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH CARE SYSTEM; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; LIFE EVENT; PERSONAL EXPERIENCE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; SOCIAL ADAPTATION; SOCIAL INTERACTION; SOCIAL STRUCTURE; STIGMA; ATTITUDE TO HEALTH; COMPLICATION; CULTURAL ANTHROPOLOGY; EPIDEMIOLOGY; PSYCHOLOGY; SUBSTANCE ABUSE; TRANSMISSION; UNITED KINGDOM;

ANTHROPOLOGY, CULTURAL; ANTIVIRAL AGENTS; GREAT BRITAIN; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C; HUMANS; QUALITATIVE RESEARCH; SUBSTANCE ABUSE, INTRAVENOUS;

ANTIVIRUS AGENT;

EID: 69249086592     PISSN: 10497323     EISSN: 15527557     Source Type: Journal    
DOI: 10.1177/1049732309341656     Document Type: Article

References (95)

1. Aceijas, C., & Rhodes, T. (2007). Global estimates of prevalence of HCV infection among injecting drug users. International Journal of Drug Policy, 18, 352-358.
2. Allsop, J., Baggott, R., & Jones, K. (2002). Health consumer groups and the national policy process. In S. Henderson & A. Peterson (Eds.), Consuming health: The commodification of health care. London: Routledge.
3. Anderson, J., Blue, C., & Lau, A. (1991). Women's perspectives on chronic illness: Ethnicity, ideology and restructuring of life. Social Science and Medicine, 33(2), 101-113.
4. Anderson, J., Wiggins, S., Rajwani, R., Holbrook, A., Blue, C., & Ng, M. (1995). Living with a chronic illness: Chinese-Canadian and Euro-Canadian women with diabetes-Exploring factors that influence management. Social Science and Medicine, 41(2), 181-195.
5. Anti-Discrimination Board of New South Wales. (2001). C-Change: Report of the enquiry into hepatitis C related discrimination. Sydney, NSW, Australia: Author.
6. Backmund, M., Meyer, K., & Edlin, B.R. (2004). Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clinical Infectious Diseases, 39, 1540-1543.
7. Bermingham, S., & Kippax, S. (1998). HIV-related discrimination: A survey of New South Wales general practitioners. Australian and New Zealand Journal of Public Health, 22, 92-97.
8. Binswanger, I., Kral, A., Bluthenthal, D., & Edlin, B.R. (2000). High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clinical Infectious Diseases, 30, 579-281.
9. Brener, L., von Hippel, W., & Kippax, S. (2007). Health care workers and discrimination towards injecting drug users with hepatitis C: Does greater contact lead to less prejudice? International Journal of Drug Policy, 18, 381-387.
10. Bryant, J., Saxton, M., Madden, A., Bath, N., & Robinson, S. (2008). Consumer participation in the planning and delivery of treatment services: The current arrangements. Drug and Alcohol Review, 27, 130-137.
11. Bury, M. (1982). Chronic illness as biographical disruption. Sociology of Health & Illness, 4(2), 167-181.
12. Butt, G., Paterson, B., & McGuinness, L. (2008). Living with the stigma of hepatitis C. Western Journal of Nursing Research, 30(2), 204-221.
13. Campbell, R., Pound, P., Pope, C., Britten, N., Pill, R., Morgan, M., et al. (2003). Evaluating meta-ethnography: A synthesis of qualitative research on lay experiences of diabetes and diabetes care. Social Science and Medicine, 56, 671-684.
14. Carricaburu, D., & Pierret, J. (1995). From biographical disruption to biographical reinforcement: The case of HIV-positive men. Sociology of Health and Illness, 17(1).
15. Charmaz, K. (1991). Good days, bad days: The self in chronic illness and time. New Brunswick, NJ: Rutgers University Press.
16. Conrad, S., Garrett, L., Cooksley, W., Dunne, M., & Macdonald, G. (2006). Living with chronic hepatitis C means "you just haven't got a normal life anymore." Chronic Illness, 2, 121-131.
17. Cooper, C., & Mills, E. (2006). Therapeutic challenges in hepatitis C-infected injection drug using patients. Harm Reduction Journal, 3, 31.
18. Copeland, L. (2004). The drug user's identity and how it relates to being hepatitis C antibody positive: A qualitative study. Drugs-Education Prevention & Policy, 11(2), 129-147.
19. Cornberg, M., Wedemyer, H., & Manns, M. (2002). Treatment of chronic hepatitis C with pegylated interferon and ribavirin [Review]. Current Gastroenterology Reports, 4, 23-30.
20. Craine, N., Walker, M., Carnwath, T., & Klee, H. (2004). Hepatitis C testing and injecting risk behaviour: The results of a UK based pilot study. International Journal of Drug Policy, 15, 115-122.
21. Crockett, B., & Gifford, S. (2004). "Eyes wide shut": Narratives of women living with hepatitis C in Australia. Women and Health, 39(4), 117-137.
22. Crofts, N., Louie, R., & Loff, B. (1997). The next plague: Stigmatization and discrimination related to hepatitis C virus infection in Australia. Health and Human Rights, 2, 87-96.
23. Davis, M., & Rhodes, T. (2004). Beyond prevention? Injecting drug user narratives about hepatitis C. International Journal of Drug Policy, 15, 123-131.
24. Davis, M., Rhodes, T., & Martin, A. (2004). Preventing hepatitis C: "Common sense," "the bug" and other perspectives from the risk narratives of people who inject drugs. Social Science & Medicine, 59, 1807-1818.
25. Day, C., Ross, J., & Dolan, K. (2003). Hepatitis C-related discrimination among heroin users in Sydney: Drug user or hepatitis C discrimination? Drug and Alcohol Review, 22, 317-321.
26. De, P., Roy, E., Boivin, J.-F., Cox, J., & Morissette, C. (2008). Risk of hepatitis C virus transmission through drug preparation equipment: A systematic and methodological review. Journal of Viral Hepatitis, 15, 279-292.
27. Dieperink, E., Ho, S.B., Thuras, P., & Willenbring, M.L. (2003). A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics, 44, 104-112.
28. Edlin, B.R., Kresina, T.F., Raymond, D.B., Carden, M.R., Gourevitch, M.N., Rich, J.D., et al. (2005). Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clinical Infectious Diseases, 40(Suppl 5), S276-S285.
29. Faye, B., & Irurita, V. (2003). Balancing perspective: The response to feelings of being condemned with the hepatitis C virus. Journal of Substance Use, 8, 92-103.
30. Fischer, B., Haydon, E., Rehm, J., Krajden, M., & Reimer, J. (2004). Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach-The case study of Canada. Journal of Urban Health, 81, 428-447.
31. Fraenkel, L., McGraw, S., Wongcharatrawee, S., & Garcia-Tsao, G. (2005). What do patients consider when making decisions about treatment for hepatitis C? American Journal of Medicine, 118, 1387-1391.
32. Fraenkel, L., McGraw, S., Wongcharatrawee, S., & Garcia-Tsao, G. (2006). Patients' experiences related to anti-viral treatment for hepatitis C. Patient Education and Counseling, 62, 148-155.
33. Frank, A. (1995). The wounded storyteller: Body, illness and ethics. Chicago: University of Chicago Press.
34. Fraser, S., & Treloar, C. (2006). "Spoiled identity" in hepatitis C infection: The binary logic of despair. Critical Public Health, 16(2), 99-110.
35. Fried, M., Shiffman, M., Reddy, K., Smith, C., Marinos, G., Goncales, F., et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347, 975-982.
36. Gifford, S.M., O'Brien, M.L., Bammer, G., Banwell, C., & Stoove, M. (2003). Australian women's experiences of living with hepatitis C virus: Results from a cross-sectional survey. Journal of Gastroenterology and Hepatology, 18, 841-850.
37. Glacken, M., Kernohan, G., & Coates, V. (2001). Diagnosed with hepatitis C: A descriptive exploratory study. International Journal of Nursing Studies, 38(1), 107-116.
38. Grebely, J., Genoway, K., Khara, M., Duncan, F., Viljoen, M., Elliott, D., et al. (2007). Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C infection. International Journal of Drug Policy, 18, 437-443.
39. Grebely, J., Raffa, J., Lai, C., Krajden, M., Fischer, B., Kerr, T., et al. (2007). Low uptake of treatment for hepatitis C virus (HCV) infection in a large community-based cohort of illicit drug users in Vancouver. Hepatology, 46, 296A.
40. Grow, J., & Christopher, S. (2008). Breaking the silence surrounding hepatitis C by promoting self-efficacy: Hepatitis C public service announcements. Qualitative Health Research, 18, 1401-1412.
41. Grundy, G., & Beeching, N. (2004). Understanding social stigma in women with hepatitis C. Nursing Standard, 19(4), 35-39.
42. Habib, S., & Adorjany, L. (2003). Hepatitis C and injecting drug use: The realities of stigmatisation and discrimination. Health Education Journal, 62(3), 256-265.
43. Hagan, H., Des Jarlais, D.C., Stern, R., Lelutiu-Weinberger, C., Scheinmann, R., Strauss, S., et al. (2007). HCV synthesis project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. International Journal of Drug Policy, 18, 341-351.
44. Harris, M. (2005). Living with hepatitis C: The medical encounter. New Zealand Sociology, 20(1), 4-19.
45. Herek, G. (1999). AIDS and stigma. American Behavioral Scientist, 42(7), 1106-1116.
46. Hopwood, M., & Treloar, C. (2005). The experiences of interferon-based treatments for hepatitis C infection. Qualitative Health Research, 15, 635-646.
47. Hopwood, M., & Treloar, C. (2008). Resilient coping: Applying adaptive responses to prior adversity during treatment for hepatitis C infection. Journal of Health Psychology, 13, 17-27.
48. Keating, G., & Curran, M. (2003). Peg-interferon alpha 2a (40Kd) plus ribavirin: A review of its use in the management of chronic hepatitis C. Drugs & Society, 63, 701-730.
49. Lenton, S., Kerry, K., Loxley, W., Tan-Quigley, A., & Greig, R. (2000). Citizens who inject drugs: The "Fitpack" study. International Journal of Drug Policy, 11, 285-297.
50. Limburg, W. (2004). Natural history, treatment and prevention of hepatitis C in injecting drug users. In J. Jager, W. Limburg, M. Kretzschmar, M. Postma, & L. Wiessing (Eds.), Hepatitis C and injecting drug use: Impact, costs and policy options Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
51. Maher, L., Li, J., Jalaludin, B., Chant, K., & Kaldor, J. (2007). High hepatitis C incidence in new injecting drug users: A policy failure ? Australian New Zealand Journal of Public Health, 31(1), 30-35.
52. Manns, M., McHutchison, J., Gordon, S., Rustgi, V., Shiffman, M., Reindollar, R., et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet, 358, 958-965.
53. Martin, E. (1994). Flexible bodies: Tracking immunity in American culture-From the days of polio to the age of AIDS. Boston: Beacon Press.
54. Matthews, G., Kronborg, I.J., & Dore, G.J. (2005). Treatment for hepatitis C virus infection among current injection drug users in Australia. Clinical Infectious Diseases, 40(Suppl 5), S325-S329.
55. McHutchison, J., Gordon, S., Schiff, E., Shiffman, M., Lee, W., Rustgi, V., et al. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine, 339, 1485-1892.
56. Ministerial Advisory Committee on AIDS Sexual Health and Hepatitis, Hepatitis C Sub-Committee. (2006). Hepatitis C virus projections working group: Estimates and projections of the hepatitis C virus epidemic in Australia 2006. Sydney, NSW, Australia: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.
57. Montagne, M. (2002). Appreciating the user's perspective: Listening to the "Methadonians." Substance Use and Misuse, 37(4), 565-570.
58. Moore, D., & Fraser, S. (2006). Putting at risk what we know: Reflecting on the drug-using subject in harm reduction and its political implications. Social Science & Medicine, 62(12), 3035-3047.
59. Murphy, E., Dingwall, R., Greatbatch Parker, S., & Watson, P. (1998). Qualitative research methods in health technology assessment: A review of the literature. Health Technology Assessment, 2, 16.
60. National Centre in HIV Epidemiology and Clinical Research. (2007). Australian NSP survey national data report 2002-2006. Sydney, NSW, Australia: Author, University of New South Wales.
61. National Institutes of Health. (2002). Consensus development conference statement: Management of hepatitis C. Hepatology, 36, S3-S20.
62. Noblit, G.W., & Hare, R.D. (1988). Meta-ethnography: Synthesising qualitative research studies. London: Sage.
63. Norman, J., Walsh, N., Mugavin, J., Stoove, M., Kelsall, J., Austin, K., et al. (2008). The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users. Harm Reduction Journal, 5(8). doi:10.1186/1477-7517-5-8.
64. Parker, R., & Aggleton, P. (2003). HIV and AIDS-related stigma and discrimination: A conceptual framework and implications for action. Social Science & Medicine, 57(1), 13-24.
65. Paterson, B. (2001). The shifting perspectives model of chronic illness. Journal of Nursing Scholarship, 33(1), 21-26.
66. Paterson, B., Backmund, M., Hirsch, G., & Yim, C. (2007). The depiction of stigmatization in research about hepatitis C. International Journal of Drug Policy, 18(5), 364-373.
67. Paterson, B., Russell, C., & Thorne, S. (2001). Critical analysis of everyday self-care decision making in chronic illness. Journal of Advanced Nursing, 35(3), 335-341.
68. Petersen, A., & Lupton, D. (1996). The new public health: Health and self in the age of risk. Sydney, NSW, Australia: Allen & Unwin. Pierret, J. (2001). Interviews and biographical time: The case of long-term HIV nonprogressors. Sociology of Health and Illness, 23(2), 159-179.
69. Public Health Resources Unit, England. (2006). Critical appraisal skills programme (CASP): Collaboration for qualitative methodologies. Retrieved October 1, 2007, from http://www.phru.nhs.uk/Doc_Links/ Qualitative%20Appraisal%20Tool.pdf
70. Rhodes, T., Prodanovic, A., Zikic, B., Kuneski, E., Pavicevic, T., Karadzic, D., et al. (2008). Trust, disruption and responsibility in accounts of injecting equipment sharing and hepatitis C risk. Health, Risk & Society, 10, 221-240.
71. Rhodes, T., & Treloar, C. (2008). The social production of hepatitis C risk among injecting drug users: A qualitative synthesis. Addiction, 103(10), 1593-1603.
72. Roy, E., Nonn, E., Haley, N., & Cox, J. (2007). Hepatitis C meanings and preventative strategies among street-involved young injection drug users in Montreal. International Journal of Drug Policy, 18, 397-405.
73. Roy, K., Hay, G., Andragetti, R., Taylor, A., Goldberg, D., & Wiessing, L. (2002). Monitoring hepatitis C virus infection among injecting drug users in the European Union: A review of the literature. Epidemiology and Infection, 129, 577-585.
74. Russo, M.W., & Fried, M.W. (2003). Side effects of therapy for chronic hepatitis C. Gastroenterology, 124(6), 1711-1719.
75. Shaw Hughner, R., & Schultz Kleine, S. (2008). Variations in lay health theories: Implications for consumer health care decision making. Qualitative Health Research, 18, 1687-1703.
76. Strathdee, S.A., Latka, M., Campbell, J., O'Driscoll, P.T., Golub, E.T., Kapadia, F., et al. (2005). Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV infected injection drug users. Clinical Infectious Diseases, 40(Suppl 5), S304-S312.
77. Sutton, R., & Treloar, C. (2007). Chronic illness experiences, clinical markers and living with hepatitis C. Journal of Health Psychology, 12(2), 330-340.
78. Sylvestre, D., Litwin, A., Clements, B., & Gourevitch, M. (2005). The impact of hepatitis C virus treatment in recovering heroin users maintained on methadone. Journal of Substance Abuse Treatment, 29, 159-165.
79. Sylvestre, D., & Zweben, J. (2007). Integrating HCV services for drug users: A model to improve engagement and outcomes. International Journal of Drug Policy, 18(5), 406-410.
80. Teesson, M., & Proudfoot, H. (Eds.). (2003). Comorbid mental disorders and substance use disorders: Epidemiology, prevention and treatment. Canberra, NSW, Australia: Australian Government Department of Health and Ageing.
81. Temple-Smith, M., Gifford, S., & Stoove, M. (2004). The lived experience of men and women with hepatitis C: Implications for support needs and health information. Australian Health Review, 27(2), 46-56.
82. Tompkins, C., Wright, N., & Jones, L. (2005). Impact of a positive hepatitis C diagnosis on homeless drug users: A qualitative study. British Journal of General Practice, 55, 263-268.
83. Treloar, C., & Fraser, S. (2007). Public opinion on NSPs: Avoiding assumptions for policy and practice. Drug & Alcohol Review, 26(4), 355-361.
84. Treloar, C., & Holt, M. (2006). Deficit models and divergent philosophies: Service providers' perspectives on barriers and incentives to drug treatment. Drugs: Education, Prevention and Policy, 13(4), 367-382.
85. Treloar, C., & Holt, M. (2007). Complex vulnerabilities as barriers to treatment for illicit drug users with high prevalence mental health comorbidities. Mental Health and Substance Use: Dual Diagnosis, 1(1), 84-95.
86. Treloar, C., & Holt, M. (2008). Drug treatment clients' readiness for hepatitis C treatment: Implications for expanding treatment services in drug and alcohol settings. Australian Health Review, 32(3), 570-576.
87. Treloar, C., & Hopwood, M. (2004). Infection control in the context of hepatitis C disclosure: Implications for education of health professionals. Education for Health, 17, 183-191.
88. Treloar, C., & Hopwood, M. (2008). "Look, I'm fit, I'm positive and I'll be all right, thank you very much": Coping with hepatitis C treatment and unrealistic optimism. Psychology, Health & Medicine, 13, 360-366.
89. Tritter, J., & McCallum, A. (2006). The snakes and ladders of user involvement: Moving beyond Arnstein. Health Policy, 76, 156-168.
90. Vickerman, P., Miners, A., & Williams, J. (2008). Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users: An economic modelling report. London: National Institute for Health and Clinical Excellence.
91. Williams, S. (2000). Chronic illness as biographical disruption or biographical disruption as chronic illness? Reflections on a core concept. Sociology of Health & Illness, 22(1), 40-67.
92. World Health Organization. (2000). Hepatitis C fact sheet. Geneva: Author.
93. Wozniak, L., Prakash, M., Taylor, M., & Wild, C. (2007). Everybody's got it, but...: Situational and strategic participation in normalized HCV discourse among injection drug users in Edmonton, Canada. International Journal of Drug Policy, 18, 388-396.
94. Zickmund, S., Bryce, C., Blasiole, J., Shinkunas, L., LaBrecque, D., & Arnold, R. (2006). Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. European Journal of Gastroenterology & Hepatology, 18(4), 381-388.
95. Zweben, A. (2001). Integrating pharmacotherapy and psychosocial interventions in the treatment of individuals with alcohol problems. Journal of Social Work Practice in the Addictions, 1, 65-80.